PaulBrentFerrellJr.MD

Hematologic Oncology

Physician

Dr. Ferrell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2015
Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2011
University of North Carolina at Chapel Hill School of MedicineClass of 2009

PubMed

18 citations
Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.
Benjamin J. Reisman, Hui Guo, Haley E. Ramsey, Madison T. Wright, Bradley I. Reinfeld
Nature Chemical Biology. 2021-12-02
5 citations
Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.
Kathryn I. Sunthankar, Matthew T. Jenkins, Candace H. Cote, Sweta B. Patel, Robert S. Welner
Leukemia. 2021-12-02
2 citations
Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.
Haley E. Ramsey, Kristy R. Stengel, James C. Pino, Gretchen Johnston, Merrida A Childress
Targeted Oncology. 2021-07-29

Lectures

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
IDH2 Mutations Induce Altered STAT Signaling and Cytokine Responses Which Are Restored By Enasidenib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018